GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.

Teva Pharmaceutical Industries temporarily halted drug production at the company’s Irvine plant in California to address issues raised by the U.S. Food and Drug Administration after a recent inspection, the company said on Oct. 4.

Novartis aims to help manufacture more than 50 million doses of BioNTech’s Covid-19 vaccine in 2021 at the Swiss drugmaker’s Stein, Switzerland fill-and-finish facility after the European Union’s drug regulator approved the bottling plant.

Moderna is adding two new production lines at the company’s rebuilt former Polaroid plant in Massachusetts to increase overall production capacity by 50 percent for its Covid-19 vaccine.

Johnson & Johnson said on March 31 the company had found a problem with a batch of the drug substance for its Covid-19 vaccine being produced by Emergent BioSolutions, and said the batch did not advance to the final fill-and-finish stage.

A large plant being used to manufacture Johnson & Johnson’s Covid-19 vaccine was cleared by U.S. regulators on March 23, setting the stage for the weekly U.S. supply to surge more than 20 percent.

Merck & Co. will help make rival Johnson & Johnson’s Covid-19 vaccine in order to boost the slower-than-promised production of the one-dose shot, U.S. President Joe Biden said on March 2.

Bristol Myers Squibb announced plans for a new manufacturing plant in Devens, Mass., adding to the company’s cell therapy network.

French healthcare company Sanofi will provide Covid-19 vaccine manufacturing support to U.S. peer Johnson & Johnson.

The cancer drugmaker pled guilty of violating the Federal Food, Drug and Cosmetic Act by failing to provide certain records to investigators in federal court.